McKesson’s strategy includes a disciplined approach to invest and position the company for growth in the areas of specialty, oncology and biopharma services.
Continuing to implement this strategy, Biologics by McKesson has reached a number of agreements to expand its offerings in 2020 the most recent of which is its selection by Taiho Oncology as a specialty pharmacy provider for INQOVI (decitabine and cedazuridine) tablets.
INQOVI is for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML), two blood malignancies.
The agreement strengthens the relationship between the two companies as Biologics is one of six specialty pharmacies used by Taiho Oncology Patient Support, and McKesson Specialty Health and McKesson Plasma and Biologics are included in a group of only four wholesalers.
Biologics, as part of a recent reorganization, is now joining McKesson’s Provider Solutions business within the Pharmaceutical Solutions and Services (PSaS) business unit.
The Provider Solutions team is a group focused on drug distribution, Group Purchasing Organization (GPO) services and practice management solutions to almost 2,500 community oncologists, as well as thousands of physicians across other specialties like rheumatology, gastroenterology, ophthalmology and neurology.
AllianceRx Walgreens Prime (AllianceRx) has also recently been selected by Taiho Oncology to participate in the limited distribution network for INQOVI. AllianceRx also participates in the specialty pharmacy distribution network for Pfizer Oncology, among others.
Takeaway: Biologics is creating an oncology ecosystem that leverages its differentiated suite of solutions across the enterprise to give patients more integrated care